Current available therapies and future directions in the treatment of malignant gliomas

Por Desjardins, Annick, Reardon, David A, Vredenburgh, James J
Publicado em 2009

Imaging descriptors improve the predictive power of survival models for glioblastoma patients

Por Mazurowski, Maciej Andrzej, Desjardins, Annick, Malof, Jordan Milton
Publicado em 2013

Experience with irinotecan for the treatment of malignant glioma

Por Vredenburgh, James J., Desjardins, Annick, Reardon, David A., Friedman, Henry S.
Publicado em 2009

Interstitial chemotherapy with biodegradable BCNU (Gliadel(®)) wafers in the treatment of malignant gliomas

Por Bota, Daniela A, Desjardins, Annick, Quinn, Jennifer A, Affronti, Mary L, Friedman, Henry S
Publicado em 2007

Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy

Por Reardon, David A, Wen, Patrick Y, Desjardins, Annick, Batchelor, Tracy T, Vredenburgh, James J
Publicado em 2008

Everolimus tablets for patients with subependymal giant cell astrocytoma

Por Turner, Scott G, Peters, Katherine B, Vredenburgh, James J, Desjardins, Annick, Friedman, Henry S, Reardon, David A
Publicado em 2011

Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients

Por Perry, Stephanie L., Bohlin, Cindy, Reardon, David A., Desjardins, Annick, Friedman, Allan H., Friedman, Henry S., Vredenburgh, James J.
Publicado em 2009

Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier

Por Di, Kaijun, Lloyd, G. Kenneth, Abraham, Vivek, MacLaren, Ann, Burrows, Francis J., Desjardins, Annick, Trikha, Mohit, Bota, Daniela A.
Publicado no Neuro Oncol (2016)

AT-22 PHASE II TRIAL OF BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION

Por Ghiaseddin, Ashley, Dunn-Pirio, Anastasie, Peters, Katherine, Vlahovic, Gordana, Herndon, James, Threatt, Stevie, Sampson, John, Friedman, Allan, Friedman, Henry, Desjardins, Annick
Publicado em 2014

SM-02 LEVETIRACETAM USAGE IN POST-OPERATIVE SEIZURE MANAGEMENT IN MALIGNANT GLIOMA

Por Kang, Jennifer, Desjardins, Annick, Healy, Patrick, Herndon, James, Lipp, Eric, Peters, Katherine, Vlahovic, Gordana, Sampson, John, Friedman, Henry, Friedman, Allan, Adamson, Cory
Publicado no Neuro Oncol (2014)

AT-20 SINGLE INSTITUTION RETROSPECTIVE REVIEW OF PERFORMANCE STATUS AND CORTICOSTEROID USE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS (PTS) TREATED ON BEVACIZUMAB (BEV)

Por Desjardins, Annick, Herndon, James, McSherry, Frances, Ravelo, Arliene, Lipp, Eric, Healy, Patrick, Peters, Katherine, Vlahovic, Gordana, Sampson, John, Friedman, Allan, Friedman, Henry
Publicado em 2014

QOL-19 PROSPECTIVE EVALUATION OF CARDIOPULMONARY FITNESS IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS RECEIVING AN ANTI-ANGIOGENIC REGIMEN

Por Ghiaseddin, Ashley, West, Miranda, Hornsby, Whitney, Freeman, Maria, Lipp, Eric, McSherry, Frances, Herndon, James, Desjardins, Annick, Friedman, Henry, Jones, Lee, Peters, Katherine
Publicado no Neuro Oncol (2015)

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinot...

Por Affronti, Mary Lou, Woodring, Sarah, Peters, Katherine B, Herndon, James E, McSherry, Frances, Healy, Patrick N, Desjardins, Annick, Vredenburgh, James J, Friedman, Henry S
Publicado no Ther Clin Risk Manag (2016)

SAFETY AND EFFICACY OF STEREOTACTIC RADIOSURGERYAND ADJUVANT BEVACIZUMAB IN PATIENTS WITH RECURRENT MALIGNANT GLIOMAS

Por Cuneo, Kyle C., Vredenburgh, James J., Sampson, John H., Reardon, David A., Desjardins, Annick, Peters, Katherine B., Friedman, Henry S., Willett, Christopher G., Kirkpatrick, John P.
Publicado em 2011

Phase I Study of Sunitinib and Irinotecan for Patients with Recurrent Malignant Glioma

Por Reardon, David A., Vredenburgh, James J., Coan, April, Desjardins, Annick, Peters, Katherine B., Gururangan, Sridharan, Sathornsumetee, Sith, Rich, Jeremy N., Herndon, James E., Friedman, Henry S.
Publicado em 2011

Expression Patterns of the Drosophila Neuropeptide CCHamide-2 and Its Receptor May Suggest Hormonal Signaling from the Gut to the Brain

Por Li, Shizhong, Torre-Muruzabal, Teresa, Søgaard, Karen C., Ren, Guilin R., Hauser, Frank, Engelsen, Signe M., Pødenphanth, Mads D., Desjardins, Annick, Grimmelikhuijzen, Cornelis J. P.
Publicado em 2013

AT-19 SINGLE INSTITUTION RETROSPECTIVE COMPARISON OF GLIOBLASTOMA (GBM) PATIENTS (PTS) INITIATED ON BEVACIZUMAB (BEV) BEFORE VERSUS AFTER RECURRENCE IN CLINICAL PRACTICE

Por Desjardins, Annick, Herndon, James, McSherry, Frances, Ravelo, Arliene, Lipp, Eric, Healy, Patrick, Boulton, Susan, Peters, Katherine, Vlahovic, Gordana, Sampson, John, Friedman, Allan, Friedman, Henry
Publicado em 2014

AT-46 VORINOSTAT AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMA: INTERIM ANALYSIS OF A PHASE II CLINICAL TRIAL

Por Peters, Katherine, Reardon, David, Randazzo, Dina, Dutton, Shelley, Edwards, Ashley, Lipp, Eric, Herndon, James, McSherry, Frances, Desjardins, Annick, Ranjan, Tulika, Vlahovic, Gordana, Friedman, Henry
Publicado em 2014

Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma

Por Peters, Katherine B., Lou, Emil, Desjardins, Annick, Reardon, David A., Lipp, Eric S., Miller, Elizabeth, Herndon, James E., McSherry, Frances, Friedman, Henry S., Vredenburgh, James J.
Publicado no Oncologist (2015)

RTRB-04 STEREOTACTIC RADIOSURGERY FOR RECURRENT HIGH-GRADE GLIOMAS: PATIENT SELECTION AND THE ROLE OF BEVACIZUMAB

Por Boyle, John, McSherry, Frances, Herndon, James, Desjardins, Annick, Sampson, John, Peters, Katherine, Chino, Junzo, Allen, Karen, Cabrera, Alvin, Kim, Grace, Friedman, Henry, Kirkpatrick, John
Publicado no Neuro Oncol (2015)